Approximately 50% of patients do not take their drugs as prescribed, thereby limiting the therapeutic effects of drugs and potentially costing healthcare services billions of dollars. As a result, there is an industry-wide trend for introducing monitoring devices to address this non-compliance. A trade-off exists in pharma between devices that are easy to use for the patient but offer limited actionable insight to the practitioner, and devices that provide more beneficial data relating to outcomes, but need to be used in a clinical setting or are otherwise more invasive to the patient. It is important to examine that trade-off and assess new advances that seek to sit in both camps.